Physician profile

Laura Lasecki Wimmer

Foot & Ankle Surgery · Fairhope, AL

NPI 1386025146

$4,928.00

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

See the full distribution for Foot & Ankle Surgery

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$547.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Prime Surgical, LLC $2,907.00 2019
Cgg Medical INC $1,207.00 2019
Organogenesis INC. $700.14 2021-2024 Puraply, Affinity, Affinity
Musculoskeletal Transplant Foundation INC. $73.48 2021
Bioventus LLC $22.32 2019
Wright Medical Technology, INC. $18.06 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Laura Lasecki Wimmer

$4,928.00

in general payments reported 2019-2025

Years
2019-2024
Top company
Prime Surgical, LLC

https://glasscript.com/doctor/1373282/laura-lasecki-wimmer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.